To determine whether elderly normal APOE E2 (APOE2) carriers exhibit slower rates of hippocampal atrophy and memory decline compared to APOE3/3 carriers. We also determined whether APOE2 carriers have less Alzheimer pathology as reflected by CSF biomarkers.
Structurally, numerous studies have reported decreased hippocampal volumes and accelerated rates of hippocampal atrophy among cognitively normal APOE4 carriers. [9] [10] [11] [12] Relatively little has been reported regarding structural differences associated with the APOE2 allele. To our knowledge, only one study has described a "protective" morphology among APOE2 carriers, manifested by greater entorhinal cortical thickness among adolescents. 13 Counterintuitively, 2 cross-sectional studies report detrimental effects of APOE2, by decreasing hippocampal volumes 10 and increasing hippocampal sulcal cavities. 14 The primary aims of this study were to test our hypotheses that cognitively normal APOE2 carriers demonstrate reduced rates of hippocampal atrophy and episodic memory decline compared to APOE3/3 carriers. We further tested the hypothesis that differences in hippocampal atrophy rates could be related to differences in underlying Alzheimer pathology.
METHODS Participants. The participants in this study were recruited between 2005 and 2008 through the Alzheimer's Disease Neuroimaging Initiative (ADNI), a longitudinal study of 819 individuals from 56 centers in the United States and Canada (229 cognitively normal, 398 with mild cognitive impairment [MCI], 192 with probable AD) designed to identify biomarkers of early AD for clinical trials. 15 The ADNI was funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private pharmaceutical companies, and nonprofit organizations, as a 5-year public-private partnership. Briefly, subjects were between the ages of 55 and 90, without clinical or structural evidence of a significant neurologic or psychiatric disease, and without systemic medical illness or laboratory abnormalities that would interfere with follow-up. Further details regarding inclusion and exclusion criteria can be found at www.adni-info.org.
In addition to the inclusion and exclusion criteria described above, the cognitively normal subjects had no memory complaints, had preserved activities of daily living, scored between 24 and 30 on a baseline Mini-Mental State Examination, 16 scored a 0 on the Clinical Dementia Rating scale, 17 and scored within the normal range on the Logical Memory II subscale (delayed paragraph recall) from the Wechsler Memory Scale-Revised (WMS-R). 18 Standard protocol approvals, registrations, and patient consents. Written consent was obtained from all subjects participating in the study, and the study was approved by the institutional review board at each participating site.
APOE genotyping and neuropsychological assessment.
All participants underwent APOE genotyping at the baseline visit. Approximately 6 mL of blood were obtained from each participant in an EDTA tube, gently mixed by inversion, and shipped at ambient temperature to a single designated laboratory within 24 hours of collection for analysis.
The participants also underwent neuropsychological assessment at baseline and every 6 months with the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) 19 and at baseline and every 12 months with the WMS-R. 18 The ADAS-Cog was used as a measure of overall cognitive function. The 30-minute delayed paragraph recall score of the WMS-R, in which a participant recounts a story that was told to him or her after the time delay, was used as a measure of episodic memory.
MRI acquisition and hippocampal volume estimation.
MRI was performed at the baseline visit, after 6 months, after 12 months, and after 24 months. The participants underwent the following 1.5-T MRI protocol (http://www.loni.ucla.edu/ADNI/Research/Cores/index.shtml), which was standardized across all sites: 2 T1-weighted MRI scans, using a sagittal volumetric magnetization-prepared rapid gradient echo (MPRAGE) sequence, with an echo time of 4 msec, repetition time of 9 msec, flip angle of 8°, and acquisition matrix size of 256 ϫ 256 ϫ 166 in the x-, y-and z-dimensions with a nominal voxel size of 0.94 ϫ 0.94 ϫ 1.2 mm. A single quality control center was designated to select the MPRAGE image with higher quality, which was corrected for system-specific image artifacts, and used for hippocampal volume estimation. 20 Scans that demonstrated severe motion artifacts or field inhomogeneity were excluded from the analysis.
The raw Digital Imaging and Communications in Medicine MRI data were downloaded from the Laboratory of Neuro Imaging Image Database Archive (http://www.loni.ucla.edu/ADNI/Data/index.shtml). The images were aligned, skull-stripped, and segmented using longitudinal FreeSurfer software, version 4.3 (http://surfer.nmr.mgh.harvard.edu/). 21 The segmented volumes were visually rated for accuracy by experienced staff and excluded from the analysis as appropriate. Bilateral hippocampal volumes, obtained from this segmentation, were summed in the analyses. CSF analysis. As described in the ADNI protocol (www.adniinfo.org), all 56 participating centers were asked to perform lumbar punctures on at least 20% of their participants. Approximately half of the participants recruited at each center underwent lumbar puncture for CSF analysis. CSF samples were banked and batch-processed at a single laboratory, as described previously. 22 Briefly, lumbar puncture was performed with a 20or 24-gauge spinal needle at the baseline visit after an overnight fast. The CSF samples were then transferred into polypropylene transfer tubes, frozen on dry ice within an hour after collection, and shipped on dry ice overnight to a single designated laboratory. After thawing for 1 hour at room temperature and gentle mixing, 0.5-mL aliquots were prepared from these samples. The aliquots were then stored in bar code-labeled polypropylene vials at Ϫ80°C and measured using the xMAP Luminex platform (Luminex Corp., Austin, TX) with Innogenetics (INNOBIA AlzBio3, Ghent, Belgium) immunoassay kit-based reagents. Monoclonal antibodies specific for ␤-amyloid (A␤), total tau, and p-tau phosphorylated at threonine-191 (p-tau) were used as reagents, which have been found to be useful in predicting AD. 23 Statistical analyses. The process of selecting the sample of 134 participants for our primary analysis is shown in figure 1 (table 1). Group differences in baseline characteristics were assessed using the Wilcoxon rank sum and Fisher exact tests. APOE2/4 participants were excluded to eliminate potential confounding of the APOE2 effect by the presence of APOE4. Four APOE3/3 subjects who converted to MCI clinically during the study period were also excluded from the analysis. Comparison of the 193 subjects whose MRI passed quality control with the remaining 36 of the normal cohort and comparison of the 134 in our sample with the other 91 of the normal cohort yielded no differences in age, gender, years of education, or Mini-Mental State Examination scores ( p Ͼ 0.05). Furthermore, approximately half of these participants (n ϭ 72) underwent lumbar puncture for CSF biomarker analysis. Comparison of the 72 participants in this subsample who underwent CSF analysis with the remainder of the normal cohort (n ϭ 157) also yielded no differences in age, gender, years of education, or Mini-Mental State Examination scores ( p Ͼ 0.05).
A linear mixed-effects model was used to assess the rate of change of hippocampal atrophy and cognition, as well as their association with APOE2, while accounting for within-subject variation. The mixed-effects model was designed to separate random variations of hippocampal volumes across subjects at baseline from the fixed effects of change over time and APOE2 carrier status. All statistical analyses were programmed in STATA version 11 (StataCorp, College Station, TX).
Since only 2 individuals were homozygous for the APOE2 allele, APOE2 carrier status was dichotomized to represent both APOE2/2 and APOE2/3 genotypes. The APOE3/3 carriers were considered the reference group for comparison. In addition, age, gender, and education in years were used as covariates in the model. Accordingly, the following mixed effects model was used:
Here, V ij represents the hippocampal volume of subject i at timepoint j, APOE2 i represents the carrier status of each subject, and t ij represents the time interval between MRI scans. (B 0 ϩ ␤ 0 ) are the coefficients for the random and fixed variations in baseline volumes. The coefficient ␤ 1 represents the fixed effects of APOE2 carrier status at baseline. Finally, (␤ 2 ϩ ␤ 3 ) are the coefficients for time-dependent changes in hippocampal volumes, irrespective (␤ 2 ) and respective (␤ 3 ) of APOE2 carrier status. The error term ⑀ ij represents random noise.
A similar model was used to evaluate rates of memory and cognitive decline. The assumption of linearity was assessed visually using plots of the mean hippocampal volumes over time and by including a quadratic term for time, which was found to be nonsignificant.
In our subgroup with CSF data, we used ordinary least squares regression to determine whether the level of each biomarker differed by APOE2 carrier status. Age, gender, and years of education were again used as covariates. Model assumptions were not violated, as assessed by plots of residuals.
RESULTS
The group characteristics are summarized in table 1. There were no significant differences in age, gender, years of education, or baseline cognition. Unadjusted levels of CSF A␤ and p-tau differed between groups at baseline. APOE2 is associated with a reduction in hippocampal atrophy rates. The results of the mixed effects models are shown ( figure 2, table 2 ). Overall, hippocampal volume decreased over time ( p Ͻ 0.001), and APOE2 carrier status was associated with slower rates of hippocampal atrophy compared to noncarriers ( p ϭ 0.004). The rate of hippocampal atrophy for APOE2 carriers was Ϫ33 mm 3 /year (95% CI Ϫ65 to ϩ0.4) or Ϫ0.5% per year, compared to Ϫ86 mm 3 / year (95% CI Ϫ102 to Ϫ71) or Ϫ1.3% per year for the APOE3/3 group. Of note, APOE2 carriers did not have larger hippocampal volumes at baseline ( p ϭ 0.93).
APOE2 is not associated with differences in rates of change of cognitive scores. WMS-R delayed paragraph recall scores increased marginally over time ( p ϭ 0.06), whereas ADAS-Cog did not change over time ( p ϭ 0.28). No difference in rates of memory or cognitive change was detected by APOE2 status.
APOE2 is associated with decreased Alzheimer pathology. In the subsample with CSF biomarkers, the crosssectional models, adjusting for covariates, demonstrated that APOE2 carriers had 34 pg/mL higher baseline levels of CSF A␤ (p ϭ 0.01, 95% CI ϩ7 to ϩ 60) and 8 pg/mL lower levels of p-tau (p ϭ 0.02, 95% CIϪ14 to Ϫ1), compared to APOE3/3 carriers. Furthermore, APOE2 carriers had 11 pg/mL lower levels of total tau, although this did not reach statistical significance (p ϭ 0.12, 95% CI Ϫ25 to ϩ3).
DISCUSSION
Our study demonstrated that cognitively normal APOE2 carriers, compared to APOE3/3 carriers, exhibit 1) slower rates of hippocampal atrophy and 2) a CSF biomarker profile suggestive of decreased underlying Alzheimer pathology.
The first major finding is that APOE2 carriers have slower rates of hippocampal atrophy, compared to carriers of the common APOE3/3 genotype. Moreover, the slower rates in APOE2 carriers cannot be explained by variations in baseline hippocampal volumes, since this was accounted for in our model. Prior literature on structural abnormalities among APOE2 carriers has been scarce and inconsistent, with only one study demonstrating increased entorhinal cortical thickness among APOE2 carriers. 13 The 2 other studies assessing cross-sectional volumetric differences among APOE2 carriers used manual tracings of the hippocampi 10 and sulcal cavities as an indirect measure of hippocampal differences, 14 which could have played a role in finding a detrimental effect of the APOE2 allele. None of the previous studies demonstrated longitudinal change. Our finding that the APOE2 allele reduces hippocampal atrophy rates is thus consistent with prior population-based evidence of this allele being protective. 2 The finding of a CSF biomarker profile reflective of decreased Alzheimer pathology among APOE2 carriers may explain the observed reduction in hippocampal atrophy rates. Several in vitro and animal studies have reported that APOE2 isoform binds A␤ more efficiently than APOE3, promotes decreased A␤ polymerization into amyloid filaments, and transports A␤ across the blood-brain barrier more quickly, suggesting an overall role in decreasing A␤ accumulation. 24 Decreased Alzheimer neuropathology associated with APOE2 has also been described in elderly normal subjects postmortem 25 and using imaging and CSF biomarkers. 26 Although only about half of our sample underwent CSF analysis, we also found evidence for increased CSF A␤, decreased p-tau, and marginally total tau. Since hippocampal volumes have been shown to reflect Alzheimer pathology 27 and predict future development of AD, 28 it is conceivable that decreased Alzheimer pathology related to cellular mechanisms of APOE2 could explain decreased hippocampal atrophy rates. On the other hand, a recent postmortem study among a population greater than the age of 90 found increased Alzheimer pathology among APOE2 carriers, despite a reduced risk of clinical dementia. 29 It is likely that other compensatory mechanisms for maintaining cognition among APOE2 carriers exist, and further follow-up of the ADNI population is required to assess how these findings may change with older age.
Since the rates of change in memory and cognitive scores were relatively minimal in the duration of follow-up, it is not surprising that the effects of APOE2 carrier status were not significant.
Our study has several limitations. First, the ADNI was intended to mimic a trial population, so Linear mixed-effects model of hippocampal atrophy rates by group the duration of follow-up was relatively short. In addition, this cohort consisted of more Caucasians, was more highly educated, and had fewer comorbidities than a community population at this age. 15 As a result, generalization of these findings should be approached with caution and further validation in prospective population-based cohorts is required. The hippocampal atrophy rates among our cohort, however, are similar to that of a recent meta-analysis which estimated a rate of Ϫ1.41%/year among normal controls. 30 Furthermore, an association between APOE2 and cerebral amyloid angiopathy, which can lead to lobar hemorrhages, has been described. 31 These would have been excluded from the ADNI with an abnormal screening MRI, thus removing a potential source for a detrimental effect of APOE2.
Finally, while we used WMS-R delayed paragraph recall as a measure of verbal memory, it is known to be confounded by practice effects, which could explain the overall upward trend in memory scores over time. Nevertheless, 52 (39%) of the subjects in our sample did demonstrate at least a 1-point decline in the paragraph recall score. Whether measuring verbal memory or practice effects, no group differences in this longitudinal measure over time were detected. This study provides evidence that the protective effect of the APOE2 genetic polymorphism is detectable in vivo, before there is evidence of cognitive impairment. We hypothesize that slower rates of neurodegeneration could be related to decreased underlying Alzheimer neuropathology.
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